Bangalore, Sep 1, 2010: Sun Pharmaceutical Industries, India, has announced that US Food and Drug Administration (FDA) has granted its subsidiary an approval to market a generic version of Strattera (atomoxetine hydrochloride) capsules.

 

Earlier, an abbreviated new drug application (ANDA) was applied for Strattera, which is a registered trademark of Eli Lilly.

 

These generic capsules are available in six strengths: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, and 100 mg.

 

Annual sale in US for these strengths of branded and generic atomoxetine hydrochloride capsules is estimated at over $ 530 million. Atomoxetine Hydrochloride capsules are indicated for the management of attention deficit hyperactivity disorder in children (aged 6 and older), teens and adults.